drugset / Trial / NCT02776371

Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori

NCT02776371

Phase 4 Completed 301 enrolled Shandong University
RandomizedParallel-groupOpen-labelTreatment

Summary

Helicobacter pylori (H. pylori) infects more than 50% of the population in the world(1), especially 47-66% in China.

Timeline

Start
2016-09
Primary completion
2018-01
Completion
2018-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1 g
Comparator Clarithromycin Small molecule 500 mg
Subject tinidazole Small molecule 500 mg
Background Rabeprazole Small molecule 10 mg

Indications

No indication recorded.